疏血通注射液辅助治疗血管性痴呆效果及安全性的系统评价和meta分析  

Systematic evaluation and meta-analysis of the efficacy and safety of Shuxuetong Injection in the treatment of vascular dementia

作　　者：王育纯 常泽 林景峰 张丹丹[1] 田丹枫 高强[1] 韩振蕴[2] WANG Yuchun;CHANG Ze;LIN Jingfeng;ZHANG Dandan;TIAN Danfeng;GAO Qiang;HAN Zhenyun(Beijing University of Chinese Medicine,Beijing100029,China;the Second Department of Encephalopathy,Dongfang Hospital,Beijing University of Chinese Medicine,Beijing100078,China)

机构地区：[1]北京中医药大学,北京100029 [2]北京中医药大学东方医院脑病二科,北京100078

出　　处：《中国医药导报》2020年第22期106-109,114,共5页China Medical Herald

基　　金：国家自然科学基金资助项目(81673910);北京市科技新星计划项目(2009A36)。

摘　　要：目的系统评价疏血通注射液辅助治疗血管性痴呆(VD)的效果和安全性。方法检索CNKI、SinoMed、万方、维普、PubMed、EMbase、Cochrane Library、Web of Science数据库,纳入疏血通注射液治疗VD的随机对照试验(RCT)。检索时限为建库至2019年5月,由2名研究者独立进行文献检索和提取资料,并对纳入文献进行质量评价,使用RevMan5.3软件进行meta分析。结果纳入8项RCT,共622例患者。meta分析结果显示,与对照组比较,疏血通辅助治疗VD能改善简易精神状态检查量表(MMSE)评分[MD=1.81,95%CI(1.35,2.27),P<0.00001]、日常生活能力量表(ADL)评分[MD=3.23,95%CI(2.03,4.42),P<0.00001],缩短P300潜伏期[MD=23.51,95%CI(16.99,30.03),P<0.00001]和增高波幅[MD=1.40,95%CI(0.71,2.08),P<0.0001]。各研究均未发生严重不良反应。结论疏血通辅助治疗VD能更好地改善患者的认知功能和日常生活能力,且安全性好,无严重不良反应。限于随访时间短、质量偏低、样本量少等因素,仍需开展更多高质量、大样本量、多中心、较长随访时间的RCT。Objective To systematically evaluate the efficacy and safety of Shuxuetong Injection in the treatment of vascular dementia(VD).Methods Randomized controlled trial(RCT)were retrieved from CNKI,SinoMed,WanFang,VIP,PubMed,EMbase,Cochrane Library,Web of Science.RCT of Shuxuetong Injection in the treatment of VD was selected.The retrieval time was from the establishment of the database to May 2019.The data was searched and extracted by two researchers independently,and the quality of the included literatures were evaluated.Meta analysis was performed using RevMan5.3 software.Results A total of 662 patients were included in eight RCTs.Meta analysis showed that compared with control group,Shuxuetong could improve mini-mental state examination(MMSE)score[MD=1.81,95%CI(1.35,2.27),P<0.00001],improve activity of daily living scale(ADL)score[MD=3.23,95%CI(2.03,4.42),P<0.00001],shorten P300 latency[MD=23.51,95%CI(16.99,30.03),P<0.00001]and increase amplitude[MD=1.40,95%CI(0.71,2.08),P<0.0001].No serious adverse reactions occurred in all studies.Conclusion Shuxuetong adjuvant therapy for VD can better improve the cognitive function and the ability of daily living,with no serious adverse reactions.Due to such factors as short follow-up time,low quality,and small sample size,more high-quality,large-sample,multicenter and longer follow-up time RCT should be carried out.

关 键 词：疏血通注射液 血管性痴呆 系统评价 META分析 

分 类 号：R743.3[医药卫生—神经病学与精神病学]